The stock of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) increased by $4.59 on Wednesday to $82.99, up 5.85 percent. The last five days have seen an average of 1,722,534 shares of common stock traded. 4 times new highs were reached in the current year, with a fall of -$5.85. The average number of shares traded over the last 20 days was 1,248,883, while the average volume over the last 50 days totaled 1,187,819.
BMRN stock dropped -1.11% since last month. On 06/14/22, the company’s shares reached a one-month low of $70.73. The stock touched a high of $94.20 on 02/10/22, after rallying from a low of $70.73 in 52 weeks. The price of BMRN stock has declined by -11.26% or -$5.85 this year, reaching a new high 4 times. Still, the stock price is down -11.90% from the 52-week high.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
There have been 27 days since BioMarin Pharmaceutical Inc. (BMRN) last reported insider trading activity on May 26. On May 26, EVP, Chief Commercial Officer Ajer Jeffrey Robert sold 1,308 shares at $78.94 each. This transaction resulted in the insider making $103,254. On May 06, BIENAIME JEAN JACQUES sold 20,000 shares at a price of US$81.00. After the transaction, the insider now owns 335,324 shares. Chief Executive Officer BIENAIME JEAN JACQUES had earlier sold 10,000 shares on May 05 for $84.14 a share. The transaction was completed for $841,400.
BioMarin Pharmaceutical Inc. (BMRN) has a trailing price-to-earnings (P/E) ratio of 509.09. Beta for the stock is 0.41. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 7.32, the price-to-book (PB) ratio of 3.28, and the price-to-cash flow ratio of 294.61.
For the three months ended March 30, BioMarin Pharmaceutical Inc.’s quick ratio was 3.30, while its current ratio was 4.90, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 75.10% percent. BioMarin Pharmaceutical Inc.’s operating margin stood at 1.60% for the same period. Based on annual data, it had gross profit of $1.38 billion and revenue of $1.85 billion.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. BMRN’s return on assets (ROA) during the last 12 months has been 0.70%. There was a -1.40% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was 0.90%.
According to BioMarin Pharmaceutical Inc.’s quarterly financial report for the quarter that ended March 30, it had $450.8 million in cash and short-term investments. A higher net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $519.36 million, while revenues rose by 6.42% to $449.81 million. It was predicted that BioMarin Pharmaceutical Inc.’s quarterly earnings would be $0.63, but it ended up being $0.17, beating the consensus by 270.60%. EBITDA was $166.32 million for the quarter. At the end of BioMarin Pharmaceutical Inc.’s most recent quarter ended March 30, its liabilities totaled 1.67 billion, while its total debt was $1.09 billion. Equity owned by shareholders amounts to $185.0 million.
Here’s a quick look at BioMarin Pharmaceutical Inc.’s (BMRN) price momentum from a technical perspective. As of 21 June, the RSI 9-day stood at 66.39%, suggesting the stock is Neutral, with a 53.70% historical volatility rate.
The stochastic %K and %D were 78.26% and 61.37% respectively, while the average true range (ATR) was 3.28. Based on the 14-day stochastic reading of 96.08%, the RSI (14) reading is 60.24%. On the 9-day MACD Oscillator, the stock is at 3.61, and the 14-day reading is at 3.03.